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1. Introduction 
Malignant pleural mesothelioma is the most common mesothelial malignancy, which arises 
from the malignant transformation of mesothelial cells that line the pleural cavity. 
Malignant pleural mesothelioma is a highly invasive disease with a very long latency and 
treatment is rarely effective, since only few patients survive more than one year after 
diagnosis (Carbone et al., 2007). Asbestos, a fibrous mineral widely used throughout the 20th 
century, has been acknowledged to being the main causative agent (Wagner, 1979).  
Although systemic chemotherapy with novel combinations of platinum-based drugs and 
antimetabolites showed some degree of success in selected patients, prognosis remains 
generally poor (Kindler, 2008;Robinson et al., 2005). The fact that the disease is often 
intrinsically resistant to treatment, combined with the notion that the majority of patients 
are elderly due to a long latency, and thus prone to complications and comorbidities, further 
limits treatment options (Ray, Kindler, 2009).  
Malignant pleural mesothelioma is still regarded as a rare disease, despite the fact that its 
incidence has been steeply rising in the last decades and is not expected to level before the 
year 2020 (Robinson et al., 2005). Increased incidence and the fact that conventional 
antitumour treatment options are ineffective, highlight the need for novel therapies for 
MPM patients and underline the urgency for implementation of more effective diagnostic, 
prognostic, predictive and, nevertheless, therapeutic targets.  
Thorough understanding of the differences between normal and malignant cells is crucial in 
the search and development of such targets. More comprehensive knowledge of tumour 
biology in general and malignant pleural mesothelioma in particular allows and facilitates 
the discovery and validation of novel potential markers. Several such potential markers can 
be found among proteins involved in the cellular pathways that mediate malignant 
transformation and, at least in part, constitute the so called hallmarks of cancer, e.g. cellular 
signalling, proliferation and apoptosis (Hanahan, Weinberg, 2000).  
This chapter focuses on presenting survivin, a cancer-specific protein involved in both 
proliferation and apoptosis regulation. Furthermore, the aim of this review is to explore 
survivin’s potential as a prognostic and therapeutic target for MPM. 
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2. Survivin as an interloper between apoptosis and proliferation 
Hanahan and Weinberg described ten so called hallmarks of cancer and defined them as 
features common to all malignancies. They consist of acquired phenotypic properties, 
rooted in the defects of key regulatory mechanisms of cells within a tissue, namely: 
unlimited replication potential, self-sufficiency in growth signals and their transduction, 
insensitivity to growth inhibitors, resistance to apoptosis, as well as sustained 
angiogenesis, adjacent and distal tissue invasion, abnormal metabolic pathways, genome 
instability, avoidance of the immune system and chronic inflammation (Hanahan, 
Weinberg, 2000;2011). Among the latter, apoptosis and proliferation deregulation are at 
the very core of malignant transformation and have thus been given special attention in 
the present paper. 
Apoptosis is an evolutionary conserved ATP-dependent type of programmed cellular death, 
executed by caspases (cysteine proteases), which lead to a progressive disruption of the cell 
structures and formation of membrane-enclosed vesicles, named apoptotic bodies. 
Apoptosis can be triggered by either intrinsic or extrinsic death signals and is regulated by 
two gene families, Bcl2 and IAP (Pizem, Cor, 2003). Survivin is a member of the IAP 
(Inhibitor of Apoptosis Protein) family and is thus an important antagonist of apoptosis, 
whose biology is discussed in more detail in the present paper.  
The very fact that survivin is a member of the IAP family and is structurally similar to IAPs, 
such as ILP-2, livin and apollon, means that initial research on this protein was focused on 
its antiapoptotic role (Li et al., 1998;Salvesen, Duckett, 2002). Even though a substantial body 
of work has been invested in elucidating survivin’s role as an apoptosis inhibitor, several 
issues are unclear and remain a subject of discussion.  
Survivin’s central role is believed to be suppression of apoptosis during embryogenesis 
(Adida et al., 1998). Survivin inhibits apoptosis on several levels. It binds and inactivates 
effector caspases 3 and 7 (Pizem, Cor, 2003). Moreover, survivin inhibits apoptosis by 
preventing mitochondrial export of the proapoptotic protein SMAC/Diablo (Lima et al., 
2009). Furthermore, survivin binds and is stabilised by the aryl hydrocarbon receptor-
binding protein (AIP), which enhances survivin’s antiapoptotic functions and helps elevate 
a cell’s antiapoptotic threshold (Kang, Altieri, 2006). Another antiapoptotic function of 
survivin is directly connected to its promitotic functions, since the binding of survivin to 
mitotic spindle microtubuli inhibits a default intrinsic triggering of cellular death during 
mitosis (Li et al., 1998). Notably, survivin expression in cancer cells helps them overcome 
intrinsic and extrinsic death signals.  
Following the discoveries of survivin’s antiapoptotic and cytoprotective functions, it was 
subsequently discovered that survivin has several other functions and is actively involved 
in cellular proliferation (Lens et al., 2003), microtubule dynamics and cellular stress 
response (Fortugno et al., 2003). Survivin is thus now regarded as a multifunctional, nodal 
protein.  
Although cellular death and cellular division seem to be directly opposite processes, they 
are indeed intimately related. And that relation makes perfect sense when tissue 
homeostasis is taken into account. Redundant, damaged or infected cells need to be 
removed by apoptosis, which does not damage adjacent cells, and substituted with new, 
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well performing ones by mitosis. Progression through the cell cycle, which allows for the 
production of new cells, and programmed cellular death, which causes loss of cells within 
tissues, share a number of control mechanisms that need to be strongly interlinked in 
order to assure normal tissue development and homeostasis. Several proteins are 
involved in the regulation of both processes. Disruption of the balance between 
proliferation and apoptosis is an important feature of malignant tumours and further 
underlines the importance of cell cycle/apoptosis regulation proteins in tumourigenesis 
(Hanahan, Weinberg, 2011).  
Cellular proliferation, like apoptosis, is a tightly regulated process. Survivin promotes 
proliferation by direct binding and stabilisation of mitotic spindle microtubuli during the 
initial stages of mitosis (Altieri, 2010) and by regulation of chromosome segregation. 
Additionally, survivin is an important part of the chromosome passenger protein complex 
(CPP) and interacts with several CPP components, assuring their stability (Fortugno et al., 
2002). In fact, Li et al. demonstrated that disruption of the survivin-mitotic spindle 
microtubuli interaction results in the loss of survivin’s antiapoptotic function and an 
increase in Caspase 3 activity, a mechanism of inter-mitotic apoptosis induction (Li et al., 
1998). The latter suggests, as mentioned previously, that survivin functions as an inhibitor of 
a default triggering of apoptosis during the G2/M phase of the cell cycle and might explain 
why survivin expression peaks at the transition from phase G2 to M (Beardmore et al., 2004). 
This means that survivin overexpression allows malignant cells to overcome proapoptotic 
checkpoints and favours aberrant progression through mitosis, regardless of critical genome 
defects, absence of growth signals or stress. 
Additionally to its promitotic and antiapoptotic functions, survivin has also been 
demonstrated to be involved in cellular stress response pathways, interacting with the 
molecular chaperone Hsp90. Hsp90 is a central stress response chaperone, which helps cells 
to adapt to stress. Fortugno et al. demonstrated that Hsp90 binds survivin and stabilises it, 
meaning that the formation of such Hsp90-survivin complexes efficiently prevents apoptosis 
and mediates cellular proliferation, overcoming the environmental stress. Since both Hsp90 
and survivin are often overexpressed in cancer, such interaction mechanisms are often 
exploited by cancer cells, allowing them to retain their proliferative potential, despite 
unfavourable environmental conditions (Altieri, 2004;Fortugno et al., 2003). 
Despite the fact that new pathways involving survivin are constantly being discovered, it is 
fairly clear that survivin is a very important cancer gene that adjuvates the accumulation of 
malignant phenotype features. In sharp contrast with its vast array of functions, survivin 
(Baculoviral IAP Repeat Containing 5; BIRC5) is a rather small protein of 16.5 kDa (142 
amino acids) and is the smallest member of the IAP family (Pizem, Cor, 2003).  
Unlike other IAP family members, survivin has only one BIR domain (Figure 1), which is 
essential for its antiapoptotic function (Ambrosini et al., 1997). Survivin spontaneously 
forms antiparallelic dimers in vitro, but novel data suggest that a monomeric form is 
required for its proper functioning (Altieri, 2008b). Within the cell, survivin can be present 
in the nucleus, cytosol and mitochondria (Mahotka et al., 2002). Its expression levels are cell-
cycle dependent, with a peak expression at the transition from phase G2 to M, which means 
that survivin expression reaches its highest point at the initial stage of cellular division 
(Beardmore et al., 2004). 
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Fig. 1. Structures of IAP family proteins, adapted from (Salvesen, Duckett, 2002). 
Survivin is encoded by the BIRC5 gene, located on chromosome 17q25 in the human 
genome and is composed of four exons and three intons (Reed, 2001). Posttranscriptional 
modifications, namely alternative intron splicing, are responsible for the formation of 
alternative survivin isoforms (Noton et al., 2006), which are described in Table 1. The exact 
meaning of alternative BIRC5 splicing is yet to be elucidated. 
BIRC5 gene expression is controlled by a TATA-less inducible promoter with a canonical 
CpG domain and three cell cycle dependent elements (CDE) (Li, Altieri, 1999). Single 
nucleotide polymorphisms in the BIRC5 promoter region and methylation of CpG domains 
have been demonstrated to affect BIRC5 expression levels (Li, Altieri, 1999;Ma et al., 
2010;Ma et al., 2011). The exact signals that trigger promoter activity and activate the 
expression of BIRC5 are not completely understood. It is possible that tumour suppressors 
repress BIRC5 expression, whereas oncogenes activate the promoter and trigger expression. 
Mirza et al. confirmed that wild-type p53, a crucial tumour suppressor, suppresses survivin 
expression (Mirza et al., 2002). 
 
Isoform Modification (relative to WT) 
survivin-2A none; wild type survivin isoform 
survivin-2B alternative exon 2 
survivin-deltaEx-3 deletion of exon 3 
survivin-3B alternative exon 3 
Table 1. Survivin isoforms, summarised from (Noton et al., 2006) 
As mentioned previously, survivin is present in both the nucleus and cytoplasm. Its various 
subcellular localisations are inevitably linked to its distinct functions. Nuclear survivin is 
thought to be involved in proliferation regulation, whereas cytoplasmic survivin has an 
anti-apoptotic role (Stauber et al., 2007). It is believed that both survivin isoform and 
phosphorylation status dictate its subcellular localisation and function, but this theory has 
not been thoroughly researched yet (Altieri, 2010;Mahotka et al., 2002). 
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It should thus be noted that survivin has a unique role in the cell, providing an interplaying 
link between cellular death and cellular division. Both apoptosis and cellular proliferation 
are often deregulated in cancer and components of both pathways could be used as 
potential anticancer therapeutic targets. 
3. Survivin in cancer  
Very few potential anticancer therapeutic targets have boosted as much promise as survivin. 
In fact, one of survivin’s most prominent features is its interesting expression pattern. Survivin 
is expressed in embryonal tissue and malignant cells, but is virtually absent from terminally 
differentiated tissues, with very limited exceptions, such as thymocytes, endothelial cells and 
bone marrow cells (Altieri, 2003a;Pizem, Cor, 2003;Sah et al., 2006). The almost exclusive 
tumour-specific expression pattern undoubtedly means that survivin has an important role in 
the development and progression of cancer (Altieri, 2008a). Survivin expression has been 
demonstrated in several types of human malignancies (Figure 2), such as medulloblastoma 
(Pizem et al., 2005), colorectal carcinoma (Sarela et al., 2000), lymphoma (Ambrosini et al., 
1997) and many others (Nachmias et al., 2004). Klabatsa et al. demonstrated that survivin is 
also expressed in malignant pleural mesothelioma (Klabatsa et al., 2005). 
 
Fig. 2. Survivin expression in cancer. A: Gallbladder adenocarcinoma. B: Medulloblastoma 
(immunohistochemistry, 400x magnification). 
Additionally to assessing survivin’s presence, retrospective analyses demonstrated that 
survivin expression levels are linked to tumour progression and patient survival. Survivin 
over-expression proved to be a negative prognostic marker in several types of cancer, like 
colorectal (Sarela et al., 2001) and hepatocellular (Ikeguchi et al., 2002) carcinoma. On the 
other hand, Kennedy et al. confirmed that survivin expression is a positive prognostic 
marker for breast cancer (Kennedy et al., 2003). In fact, increased survivin expression 
correlated with more pronounced disease progression and a more aggressive phenotype, 
poorer response to treatment and shortened patient survival (Sah et al., 2006). 
It is now generally accepted that survivin is both a negative prognostic marker and a 
positive predictive marker, since its expression reliably predicts response to treatment and 
disease progression (Kato et al., 2001). Moreover, it is possible that an increase in survivin 
expression might improve a tumour’s response to therapy, since high-survivin tumors tend 
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to be more aggressive and proliferative and thus more likely to respond to cytostatic 
treatment (Petrarca et al., 2011; Span et al., 2006). 
Besides survivin’s role in cancer progression, its sharp tumour-specific expression pattern 
means that survivin is a promising potential therapeutic target for many types of cancer. 
Several preclinical and early-stage clinical studies have indeed demonstrated the feasibility 
and effectiveness of survivin-based anticancer treatments (Altieri, 2003b).  
4. The role of survivin in malignant pleural mesothelioma 
4.1 Prognostic role 
As mentioned previously, a straightforward negative prognostic value for survivin has been 
confirmed for several types of cancer throughout a vast array of retrospective studies. But 
very few studies on survivin’s prognostic and predictive role in malignant pleural 
mesothelioma have been published so far (summarised in Table 2).  
Unfortunately, as Table 2 indicates, results of those studies are still conflicting. Nevertheless, 
it appears that survivin has a negative impact on survival of malignant pleural 
mesothelioma patients, although the numbers of patients included in the studies were 
generally low. Notwithstanding the latter, it is important to note that those studies 
unanimously confirmed that survivin indeed is extensively expressed in malignant pleural 
mesothelioma (Figure 3).  
 
Fig. 3. Survivin expression in different histological types of malignant pleural mesothelioma. 
A: epitheloid histological type, B: biphasic histological type, C: sarcomatoid histological type 
(immunohistochemistry, 400x magnification). 
As for those studies, differences in survivin detection and expression quantification methods 
might complicate any attempts at data comparison. But when the immunohistochemistry-
based studies from Table 2 are selected and compared, striking differences are observed in the 
numbers of patients with survivin-positive tumours. Gordon et al. detected 76 % of survivin 
positive malignant pleural mesotheliomas (Gordon et al., 2007), which is in concordance with 
the 77 % of survivin positive malignant pleural mesotheliomas detected by (Klabatsa et al., 
2005), whereas Kleinberg et al. demonstrated survivin expression in 64 % of malignant pleural 
mesothelioma patients included in their study (Kleinberg et al., 2007). In comparison, in our 
recently published paper, all (100 %) of the malignant pleural mesothelioma specimens from 
101 patients analysed were survivin positive, with a median level of 67 % of survivin positive 
tumour cell nuclei (Hmeljak et al., 2011).  
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Those results, although very broad-range and seemingly inconsistent, underline a very 
important point: survivin is present and actively expressed in malignant pleural 
mesothelioma. 
 
Authors Year  Patients *Methods 
Correlation 
with survival
Reference
Klabatsa  
et al. 
2005 32 immunohistochemistry positive
(Klabatsa 
et al., 2005)
Gordon et al. 2007 66 
immunohistochemistry, qRT-
PCR 
negative
(Gordon 
et al., 2007)
Kleinberg 
et al. 
2007 77 
immunohistochemistry, western 
blot 
non 
significant
(Kleinberg 
et al., 2007)
Lan et al. 2010 44 immunocytochemistry, qRT-PCR negative
(Lan 
et al., 2010)
Hmeljak et al. 2011 101 immunohistochemistry 
non 
significant
(Hmeljak 
et al., 2011)
*Only patients with malignant pleural mesothelioma are included, although some of the studies 
comprised malignant peritoneal mesothelioma and reactive pleuritis patients. 
Table 2. Overview of studies on the prognostic role of survivin in malignant pleural 
mesothelioma 
And although its prognostic value in malignant pleural mesothelioma has not been 
conclusively assessed yet, survivin’s role as a potential therapeutic target should not be 
dismissed. 
4.2 Therapeutic role 
Currently, malignant pleural mesothelioma treatment is consisted of platinum-based 
systemic chemotherapy with several additional combinations. One of the most successful 
approaches is combined systemic chemotherapy with cisplatin and pemetrexed (Belli et al., 
2009). Surgical resection of the tumour is possible only in selected cases, which are rare, due 
to the fact that most patients are diagnosed at an advanced stage of the disease, when 
debulking surgery becomes too dangerous (Kindler, 2008). Another important obstacle of 
present therapies is the fact that malignant pleural mesothelioma often develops resistance 
to therapeutic approaches, rendering them ineffective.  
Since conventional therapies regularly fail, a surprisingly high number of novel therapeutic 
approaches have been recently (and are being currently) explored. Such intensive research is 
motivated by increasing numbers of patients and the absence of current effective therapies 
(Ray, Kindler, 2009). It is a pleasant surprise that such an investment is being made in the 
treatment of a fairly rare disease. Among those novel strategies, special attention has been 
devoted to antisurvivin therapies, which have been extensively tested in the preclinical 
setting. Survivin inhibition resulted in decreased survival of malignant pleural 
mesothelioma cells (Xia et al., 2002) and increased sensitivity to radiotherapy (Kim et al., 
2007). Data from those studies indicate that posttranscriptional targeting of survivin 
increases the rates of both spontaneous and radiation-induced apoptosis and highlight the 
www.intechopen.com
Mesotheliomas – Synonyms and Definition, Epidemiology, Etiology,  
Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis 
 
218 
central role of survivin in maintainig apoptosis resistance and mitotic potential of malignant 
pleural mesothelioma cells. Moreover, use of conditionally replicative adenoviruses 
containing the BIRC5 promoter increased apoptosis in both in vitro and in vivo models of 
malignant pleural mesothelioma (Zhu et al., 2006).  
Antisurvivin treatment approaches include not only posttranscriptional knockdown with 
antisense oligonucleotides or siRNA molecules. Low molecular weight chemical inhibitors, 
such as YM155 (Nakahara et al., 2007), and immunogenic peptides, such as survivin-2B80-88 
(Tsuruma et al., 2004) are being tested in the preclinical and early-phase clinical setting for 
breast, lung and colorectal cancer. Promising results of such antisurvivin therapies, applied 
to other cancer types (Hansen et al., 2008; Olie et al., 2000;Tsuruma et al., 2008), further 
confirm the feasibility and effectiveness of antisurvivin therapeutic approaches for the 
treatment of malignant pleural mesothelioma patients.  
Our group recently performed a pilot in vitro experiment, in which a combination of survivin 
knockdown by siRNA (Stealth® siRNA BIRC5HSS179403; Invitrogen, Carlsbad, CA, USA) 
and hypotonic chemotherapy with cisplatin (cis-diamminedichloroplatinum, CDDP) dissolved 
in ultrapure water, has been administered to mesothelioma cell line MSTO-211H. The survival 
of treated cells was assessed by the clonogenic assay (Figure 4). We found that the combination 
of survivin silencing and administration of a hypotonic solution of cisplatin very effectively 
reduced survival of MSTO-211H cells compared to survivin silencing only (p<0.001) and also 
compared to survivin silencing and application of isotonic cisplatin dissolved in phosphate 
buffered saline (p=0.005). Our preliminary results suggest that inhibition of survivin 
effectively reduces the survival of malignant pleural mesothelioma cells. Moreover, the effect 
is substantially amplified when a combined approach of gene therapy and chemotherapy with 
cisplatin is applied. The exact nature of the observed combined antitumour effect (whether it is 
additive or synergistic) was not determined in the present phase of experiments, but it should 
undoubtedly be interesting to assess. 
 
Fig. 4. Survival fractions of MSTO-211H cells after transfection with Stealth® siRNA 
BIRC5HSS179403 and subsequent chemotherapy with cisplatin.  
www.intechopen.com
 
The Central Role of Survivin in Proliferation and Apoptosis of Malignant Pleural Mesothelioma  
 
219 
Nowadays, malignant pleural mesothelioma rarely responds to conventional treatment and 
prognosis remains poor, despite extensive preclinical research and improvement in 
diagnosis. Novel, locally administered targeted therapies are promising, since pleural 
mesothelioma has some features that indicate the feasibility of such therapies. Surface 
accessibility of the tumour and predominantly local spread of the disease are characteristics 
that would allow successful local gene-therapy-based treatment (Albelda et al., 2009), such 
as antisurvivin siRNAs or antisense oligonucleotides. 
Preclinical research on therapeutic targeting of survivin in malignant pleural mesothelioma 
has confirmed the effectiveness and feasibility of such approaches, especially when 
combined with existing conventional therapies and has laid a strong foundation for 
translation into the clinic. 
4.3 Biological and ethiological role 
Notwithstanding the widely acknowledged and studied presence of survivin in malignant 
pleural mesothelioma or its potential therapeutic value, very little is known about the actual 
mechanisms of activation of the BIRC5 gene during malignant transformation of mesothelial 
cells. It has been suggested that activated oncogenes might trigger BIRC5 expression, since 
Falleni et al. demonstrated a gradual increase in survivin mRNA from normal mesothelial 
cells through inflammatory pleuritis and malignant mesothelioma (Falleni et al., 2005). The 
latter indicates that survivin expression increases during the phases of malignant 
transformation and is correlated with a progressively increasing malignant phenotype. It 
has not, however, been elucidated, whether increased survivin expression is a cause or a 
consequence of malignant transformation. And even though thorough retrospective 
research might not manage to elucidate the value of survivin expression levels as a 
malignant pleural mesothelioma prognostic marker, survivin will still remain an intriguing 
and promising potential therapeutic target.  
5. The role of survivin in malignant peritoneal mesothelioma 
Although the primary focus of the present text is malignant pleural mesothelioma, the latter 
is not the only form of mesothelial malignancy. Malignant peritoneal mesothelioma (MePM) 
is a much rarer manifestation of mesothelial malignancies, accounting for 20 - 33 % of all 
malignant mesotheliomas (Bridda et al., 2007). Although the biology of malignant peritoneal 
mesothelioma remains largely unclear, this form of mesothelioma is known to arise from 
and spreads along the peritoneal mesothelium, remaining confined to the peritoneal cavity 
for most of its natural history (Deraco et al., 1999). Similarly to pleural mesothelioma, 
malignant peritoneal mesothelioma is characterised by a poor prognosis and poor response 
to treatment. Conversely, the importance of novel potential prognostic and therapeutic 
targets is just as urgent as in pleural mesothelioma. Zaffaroni et al. demonstrated that 
survivin is expressed in malignant peritoneal mesothelioma and its expression is a negative 
prognostic marker. Moreover, the same study confirmed that survivin knockdown using 
RNA interference markedly decreased MPeM cell survival in vitro (Zaffaroni et al., 2007). 
6. Conclusions 
The aim of modern anticancer treatment strategies is a “clean” removal of malignant cells 
with limited or, preferably, no damage to adjacent normal tissues. Despite recent advances 
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in anticancer treatment, malignant pleural mesothelioma remains a fatal disease with an 
extremely poor prognosis. Several retrospective studies confirmed high levels of survivin 
expression in malignant pleural mesothelioma, but failed to conclusively assess its 
prognostic significance. On the other hand, survivin targeting proved to be an effective 
approach for malignant pleural mesothelioma treatment. Unfortunately, several important 
pieces of the survivin-mesothelioma story are still missing and a lot of research is still 
awaiting.  
The present review only briefly explored the issue and we hope it helped pinpoint some of 
the missing bits of information that need to be clarified for a thorough understanding of the 
matter. It is our firm belief that combining survivin targeting with local or systemic 
conventional therapies would be a valuable therapeutic strategy for mesothelioma patients. 
Current preclinical data are extensive and incouraging and we can only hope that 
translation in the clinical setting will be prompt and successful. Malignant pleural 
mesothelioma is, in fact, a deadly disease and still has one of the worst prognoses among all 
malignancies. Research and validation of novel targets can bring new hope to patients, who 
often find themselves frustrated by the lack of effective treatment options. And in the case of 
malignant pleural mesothelioma, the numbers of those patients are increasing steeply at this 
very moment. 
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